160 related articles for article (PubMed ID: 17990179)
1. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.
Rodríguez J; Gutierrez A; Palacios A; Navarrete M; Blancas I; Alarcón J; Caballero MD; De Mattos SF; Gines J; Martínez J; Lopez A
Leuk Lymphoma; 2007 Nov; 48(11):2172-8. PubMed ID: 17990179
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
3. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
López A; Gutiérrez A; Palacios A; Blancas I; Navarrete M; Morey M; Perelló A; Alarcón J; Martínez J; Rodríguez J
Eur J Haematol; 2008 Feb; 80(2):127-32. PubMed ID: 18005385
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
[TBL] [Abstract][Full Text] [Related]
5. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Belayachi L; Bento L; García-Recio M; Sánchez JM; Villalonga P; Gutiérrez A; Fernández de Mattos S
Br J Haematol; 2016 Sep; 174(6):899-910. PubMed ID: 27220900
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
[TBL] [Abstract][Full Text] [Related]
9. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Garbo LE; Flynn PJ; MacRae MA; Rauch MA; Wang Y; Kolibaba KS
Invest New Drugs; 2009 Oct; 27(5):476-81. PubMed ID: 18953490
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma.
Sampol A; Rodriguez J; Galmés B; Gutierrez A; Besalduch J
Leuk Lymphoma; 2004 Jun; 45(6):1289-91. PubMed ID: 15360015
[TBL] [Abstract][Full Text] [Related]
11. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
Cazelles C; Belhadj K; Vellemans H; Camus V; Poullot E; Gaulard P; Veresezan L; Itti E; Becker S; Carvalho M; Dupuis J; Le Bras F; Lemonnier F; Roulin L; El Gnaoui T; Jardin F; Mounier N; Tilly H; Haioun C
Leuk Lymphoma; 2021 Sep; 62(9):2161-2168. PubMed ID: 33764240
[TBL] [Abstract][Full Text] [Related]
13. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Eom HS; Kim JS; Lee YY; Oh SJ; Lee DH; Suh C
Invest New Drugs; 2011 Feb; 29(1):154-60. PubMed ID: 19756371
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Mounier N; El Gnaoui T; Tilly H; Canioni D; Sebban C; Casasnovas RO; Delarue R; Sonet A; Beaussart P; Petrella T; Castaigne S; Bologna S; Salles G; Rahmouni A; Gaulard P; Haioun C
Haematologica; 2013 Nov; 98(11):1726-31. PubMed ID: 23753028
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
19. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A
Cancer; 2008 Feb; 112(4):831-6. PubMed ID: 18085611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
